Fenofibrate reduces postprandial hypertriglyceridemia in CD36 knockout mice

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 6, 2010, Pages 610-618

  Sandoval, José C ^a   Nakagawa Toyama, Yumiko ^b   Masuda, Daisaku ^a   Tochino, Yoshihiro ^a   Nakaoka, Hajime ^a   Kawase, Ryota ^a   Yuasa Kawase, Miyako ^a   Nakatani, Kazuhiro ^a   Inagaki, Miwako ^a   Tsubakio Yamamoto, Kazumi ^a   Ohama, Tohru ^a   Nishida, Makoto ^b   Ishigami, Masato ^a   Komuro, Issei ^a   Yamashita, Shizuya ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Apolipoprotein B 48; CD36 knockout mice; Fenofibrate; Postprandial hypertriglyceridemia

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; CD36 ANTIGEN; CHYLOMICRON; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTRIGLYCERIDEMIA; INTESTINE LYMPH; ISCHEMIC HEART DISEASE; KNOCKOUT MOUSE; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; MOUSE; NONHUMAN; POSTPRANDIAL STATE; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING; WILD TYPE; ANIMAL; BIOSYNTHESIS; DEFICIENCY; INTESTINE; METABOLISM;

ANIMALS; ANTIGENS, CD36; CHYLOMICRONS; FENOFIBRATE; HYPERTRIGLYCERIDEMIA; INTESTINES; METABOLIC SYNDROME X; MICE; MICE, KNOCKOUT; POSTPRANDIAL PERIOD;

EID: 77954704757     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.3988     Document Type: Article

References (27)

1. Third report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation and Treatment of High Blood cholesterol in Adults (Adult treatment panel III). Final report. Circulation, 2002; 106: 3163-3223
2. Carr D, Utzschneider K, Hull R, Kodama K, Retzlaff B, Brunzell J, Shofer J, Fish B, Knopp R, Kahn S: Intraabdominal fat is a major determinant of the national cholesterol education program adult treatment panel III criteria for the metabolic syndrome. Diabetes, 2004; 53: 2087-2094
3. Alberti G: Introduction to the metabolic syndrome. Eur Heart J (Suppl), 2005; 7: D3-D5
4. Austin MA, Hokanson JE, Edwards KL: Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol, 1998; 81: 7B-12B
5. Assmann G, Schulte H, Funke H, von Eckardstein A: The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J, 1998; 19 (Suppl M): M8-M14
6. Nordestgaard B, Benn M, Schnohr P, Tybjærg-Hansen A: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA, 2007; 298: 299-308
7. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA, 2007; 298: 309-316
8. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG: Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA, 2008; 300: 2142-2152
9. Stalenhoef AF, de Graaf J: Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL. Curr Opin Lipidol, 2008; 19: 355-361
10. Baillie AG, Coburn CT, Abumrad NA: Reversible binding of long-chain fatty acids to purified FAT, the adipose CD36 homolog. J Membr Biol, 1996; 153: 75-81
11. Su X, Abumrad NA: Cellular fatty acid uptake: A pathway under construction. Trends Endocrinol Metab, 2009; 20: 72-77
12. Kuwasako T, Hirano K, Sakai N, Ishigami M, Hiraoka H, Yakub MJ, Yamauchi-Takihara K, Yamashita S, Matsuzawa Y: Lipoprotein abnormalities in human genetic CD36 deficiency associated with insulin resistance and abnormal fatty acid metabolism. Diabetes Care, 2003; 26: 1647-1648
13. Yamashita S, Hirano K, Kuwasako T, Janabi M, Toyama Y, Ishigami M, Sakai N: Physiological and pathological roles of a multi-ligand receptor CD36 in atherogenesis; insights from CD36-deficient patients. Mol Cell Biochem, 2007; 299: 19-22
14. Goudriaan JR, den Boer MA, Rensen PC, Febbraio M, Kuipers F, Romijn JA, Havekes LM, Voshol PJ: CD36 deficiency in mice impairs lipoprotein lipase-mediated triglycerides clearance. J Lipid Res, 2005; 46: 2175-2181
15. Masuda D, Hirano K, Oku H, Sandoval JC, Kawase R, Yuasa-Kawase M, Yamashita Y, Takada M, Tsubakio Yamamoto K, Tochino Y, Koseki M, Matsuura F, Nishida M, Kawamoto T, Ishigami M, Hori M, Shimomura I, Yamashita S: Chylomicron remnants are increased in the postprandial state in CD36 deficiency. J Lipid Res, 2009; 50: 999-1011
16. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator activated receptors (PPARs): Tissue distribution of PPARα, β and γ in the adult rat. Endocrinology, 1996; 137: 354-366
17. Rosenson RS, Helenowski IW, Wolff DA, Rademaker AW, Huskin AL: Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care, 2007; 30: 1945-1951
18. The FIELD study investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet, 2005; 366: 1849-1861
19. Moore KJ, J El Khoury J, Medeiros LA, Terada K, Geula C, Luster AD, Freeman MW: A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J Biol Chem, 2002; 277: 47373-47379
20. Okazaki M, Usui S, Fukui A, Kubota I, Tomoike H: Component analysis of HPLC profiles of unique lipoprotein subclass cholesterols for detection of coronary artery disease. Clin Chem, 2006; 52: 2049-2053
21. Bollman, JL, Cain JC, Grindlay JH: Techniques for the collection of lymph from the liver, small intestine, or thoracic duct of the rat. J Lab Clin Med, 1949; 33: 1349-1352
22. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J: PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J, 1996; 15: 5336-5348
23. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation, 1998; 98: 2088-2093
24. Srivastava RA, Jahagirdar R, Azhar S, Sharma S, Bisgaier CL: Peroxisome proliferators activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice. Mol Cell Biochem, 2006; 285: 35-50
25. Ginsberg HN, Fisher EA: The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism. J Lipid Res, 2009; 50 Suppl: S162-166
26. Fu T, Mukhopadhyay D, Davidson NO, Borensztajn J: The peroxisome proliferators-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions. J Biol Chem, 2004; 279: 28662-28669
27. Améen C, Edvardsson U, Ljungberg A, Asp L, Akerblad P, Tuneld A, Olofsson SO, Lindén D, Oscarsson J: Activation of peroxisome proliferators-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver. J Biol Chem, 2005; 280: 1224-1229